Intermediately, susceptible strains were considered to be resistant. All laboratory testing was performed according to manufacturer specifications for that instrument in accordance with practices recommended by CLSI.
Multidrug resistant A. baumannii (MDR-AB) is classically recognized and defined if it is resistant to three or more classes of antibiotics. Statistical analysis was done using a t-test, and P B0.05 was considered significant. Table 1 depicts the resistance profiles of all the cases and consequently the fluctuations in the susceptibility patterns during the study years. Table 2 among the ICU patients is alarming in the hospital care settings.
Our retrospective study suggests that there was a substantial increase in antimicrobial resistance and a relative increase in frequency of the MDR predominating in the blood culture isolates of A. baumannii. An optimal treatment for A. baumannii infections has not been established, especially for MDR-AB. Decisions on treatment should be made on a case-by-case basis by a health care provider. Extensively resistant A. baumannii strains remain generally susceptible to polymyxins (colistin and polymyxin B). Therefore, valid infection control practices and judicious antibiotic strategies are necessary to contain the outbreaks of MDR-AB in nosocomial settings, and clinical alternatives for therapy is mandatory for improved management of infections due to MDR-AB. CFZ  CFN  CIP  GEN  MERO  NET  AUG  TM-SXT   2005  49  29  35  41  51  29  31  12  15  39  29   2006  48  35  30  48  52  35  44  35  22  62  37   2007  85  37  22  46  57  42  44  35  21  51  42   2008  106  50  51  53  59  49  53  47  36  61  46   2009  99  50  60  58  71  60  55  55  42  78  47   2010  110  44  42  54  60  47  42  51  32  70 44 
